Guardian Pharmacy Services, Inc.
Rank #39Op. LeverageGRDN · NYSE · Healthcare
Guardian Pharmacy Services, Inc. (GRDN) — Rank #39 by gross profitability (GP/assets 0.66) · ROE 19.1% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001802255 · all metrics point-in-time as of the filing date.
About
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States.
Show moreShow less
The company's individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; GuardianShield Programs for LTCFs; Order Entry QA Analyzer, which utilizes real-time rules- engine technology to examine prescriptions and detect omissions and/or errors before they become a customer service problem; and Medication Spend Analyzer to break down the monthly drug spending for each of the LTCFs. Guardian Pharmacy Services, Inc.
was founded in 2003 and is headquartered in Atlanta, Georgia.
- Industry
- Medical Care Facilities
- Sector
- Healthcare
- State
- GA
- Filer Category
- Accelerated filer
- Fiscal Year End
- December 31
- Website
- guardianpharmacy.com
Price History
Company Snapshot
P/E and reverse DCF are the primary valuation lenses at this stage.
Market Cap
$2.98B
P/E (annual)
—
P/S (annual)
2.1
P/B
11.6
P/OCF (annual)
29.8
Shareholder Yield
—
Employees
3,600
Industry
Medical Care Facilities
Exchange
NYSE
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/1 passTerry Smith quality gate
Passes 2/5 Terry Smith thresholds1 of 5 threshold not computable from filed data.
Operating margin expansion and free cash flow are the primary reads at this stage.
Profitability
Gross profitability (GP / assets)
0.66
Primary signal (Novy-Marx).
6th of 14 SIC 59 peers
Return on equity
19.1%
Gross margin
20.2%
12th of 14 SIC 59 peers
Revenue growth (YoY)
17.9%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2024 | 2025 | |
|---|---|---|
| Revenue vs COGS | ||
| Revenue vs OpEx | ||
| Op. Income vs Revenue |
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.72
2nd of 10 SIC 59 peers (best = lowest)
Current ratio
1.65×
8th of 14 SIC 59 peers
Quick ratio
1.26×
Net cash
$89.81M
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$86.84M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
0.76
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
1.0%
Stock-based comp intensity.
Piotroski F-Score
F-Score
N/A
Only 8/9 components determinable.